سعر فاجلوزينو 25 مجم 2024

Empagliflozin 25 mg film-coated tablets, pack of 30 (3 strips), an oral SGLT2 inhibitor marketed in Egypt under the brand Faglozino (Inspire / Debeiky).

• Adjunct to diet and exercise to improve glycaemic control in adults and paediatric patients aged 10 years and older with type 2 diabetes mellitus.Population: Adults and children >=10 yearsDailyMed (US National Library of Medicine)
• To reduce the risk of cardiovascular death in adults with type 2 diabetes mellitus and established cardiovascular disease.Population: AdultsDailyMed (US National Library of Medicine)
• To reduce the risk of cardiovascular death and hospitalisation for heart failure in adults with heart failure (labelled dose 10 mg once daily).Population: AdultsDailyMed (US National Library of Medicine)

• Most common adverse reactions (>=5%): urinary tract infections and female genital mycotic infections.International label, same formulation · DailyMed (US National Library of Medicine)

• Hypersensitivity to empagliflozin or any excipient (reactions such as angioedema have occurred).International label, same formulation · DailyMed (US National Library of Medicine)

• Ketoacidosis (including in type 1 diabetes and other ketoacidosis): assess for ketoacidosis regardless of blood glucose and discontinue if suspected; not for glycaemic control in type 1 diabetes.International label, same formulation · DailyMed (US National Library of Medicine)
• Volume depletion: assess volume status and renal function before starting, especially in renal impairment, the elderly or patients on loop diuretics.International label, same formulation · DailyMed (US National Library of Medicine)
• Genitourinary infections including urosepsis, pyelonephritis, necrotising fasciitis of the perineum (Fournier's gangrene) and genital mycotic infections: monitor and treat promptly.International label, same formulation · DailyMed (US National Library of Medicine)

• DiureticsIncreased urine volume and frequency may enhance the potential for volume depletion; assess volume status and renal function before starting.DailyMed (US National Library of Medicine)
• Insulin or insulin secretagogues (e.g. sulfonylureas)Increased risk of hypoglycaemia; lower doses of insulin or the secretagogue may be required.DailyMed (US National Library of Medicine)
• LithiumSGLT2 inhibitors may decrease serum lithium concentrations; monitor lithium levels more frequently at initiation and dose changes.DailyMed (US National Library of Medicine)

• Based on animal data showing adverse renal effects, not recommended during the second and third trimesters; human data are insufficient to determine a drug-associated risk of birth defects or miscarriage.International label, same formulation · DailyMed (US National Library of Medicine)
• Not recommended while breastfeeding: empagliflozin is present in rat milk and may affect the developing infant kidney.International label, same formulation · DailyMed (US National Library of Medicine)

• Empagliflozin: Inhibits SGLT2 in the proximal renal tubule, reducing reabsorption of filtered glucose and increasing urinary glucose excretion (US label).